fingolimod hydrochloride has been researched along with Adverse Drug Event in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK | 1 |
| Ataei, S; Esfahani, ME; Jenabi, E; Sahraian, MA; Salehi, AM | 1 |
| Goh, LY; Harvey, JP; Jackson, TL; Kirthi, V; Silber, E | 1 |
| Behrje, R; David, OJ; Hara, H; Lates, CD; Pal, P; Schmouder, R | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Albrecht, H; Cornelissen, C; Couto, CA; Findlay, JA; Haas, J; Klotz, L; Lang, M; Lassek, C; Schmidt, S; Tackenberg, B; Ziemssen, T | 1 |
| Chard, D; Chataway, J; Trip, A | 1 |
| Wise, J | 1 |
| Graham-Rowe, D | 1 |
| Haas, J; Hartung, HP; Linker, RA; Meergans, M; Ortler, S; Tracik, F | 1 |
| Ferguson, R; Knoflach, A; Kunzendorf, U; Mulgaonkar, S; Oppenheimer, F; Patel, Y; Russ, G; Tedesco, H; Walker, R | 1 |
2 review(s) available for fingolimod hydrochloride and Adverse Drug Event
| Article | Year |
|---|---|
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
Topics: Azetidines; Benzyl Compounds; Bradycardia; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hypertension; Indans; Multiple Sclerosis; Oxadiazoles; Randomized Controlled Trials as Topic; Risk; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2021 |
Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review.
Topics: Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
1 trial(s) available for fingolimod hydrochloride and Adverse Drug Event
| Article | Year |
|---|---|
FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.
Topics: Adult; Biopsy; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lung; Male; Middle Aged; Propylene Glycols; Sphingosine; Time Factors | 2006 |
8 other study(ies) available for fingolimod hydrochloride and Adverse Drug Event
| Article | Year |
|---|---|
Real-world incidence of fingolimod-associated macular oedema.
Topics: Adult; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; London; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tomography, Optical Coherence | 2020 |
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.
Topics: Adolescent; Adult; Area Under Curve; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Healthy Volunteers; Humans; Male; Middle Aged; Young Adult | 2018 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Prospective Studies; Time Factors | 2019 |
New oral drugs for the treatment of multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Therapy Management; Multiple Sclerosis; Nitriles; Toluidines; United Kingdom | 2016 |
Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
Topics: Death, Sudden; Disclosure; Drug-Related Side Effects and Adverse Reactions; Europe; Fingolimod Hydrochloride; Government Agencies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
[Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].
Topics: Adult; Case-Control Studies; Comorbidity; Compassionate Use Trials; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Europe; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Prevalence; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |